UNSPSC 51361917: Pentobarbital or pentobarbitone

This classification denotes a barbiturate with the molecular formula C11H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I4744080IR, chemically known as 2,4,6 (1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)-, monosodium salt but generally known as pentobarbital, which bears US NIH Compound Identifier 4737. European Medicines Agency schedules Pentobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09699MIG. The term PENTOBARBITAL is an International Non-Proprietary Name.

UNSPSC 51361917 Pentobarbital or pentobarbitone is a Commodity code that encompasses controlled pharmaceutical substances used in medical, veterinary, and end-of-life care settings. However, the recent state and local opportunities tagged to this code do not reflect procurement of pentobarbital itself; instead, they document solicitations for naloxone (an opioid antagonist), safe drug deactivation systems, and broad-based generic pharmaceutical and over-the-counter product contracts. The mismatch suggests either tagging error in the source records or that state procurement systems are applying this code to a broader pharmaceutical-supply family than the code's name implies. Actual buying under this code's nominal scope—pentobarbital for controlled medical use—shows no recent state or local solicitation activity in the source material.

The geographic spread of pharmaceutical procurement activity (when abstracting beyond the pentobarbital code-name mismatch) spans Florida, Texas, and Minnesota through a mix of county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: date discrepancy in source); the Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon. The code shows limited, inconsistent recent activity directly aligned with pentobarbital procurement.